PDL-1 cpd 10

CAS No. 2767424-13-3

PDL-1 cpd 10( —— )

Catalog No. M37623 CAS No. 2767424-13-3

PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 76 Get Quote
5MG 113 Get Quote
10MG 187 Get Quote
25MG 380 Get Quote
50MG 545 Get Quote
100MG 745 Get Quote
200MG 981 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PDL-1 cpd 10
  • Note
    Research use only, not for human use.
  • Brief Description
    PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
  • Description
    PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2767424-13-3
  • Formula Weight
    377.44
  • Molecular Formula
    C21H23N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (331.18 mM; Ultrasonic (<60°C)
  • SMILES
    CC1=C(C=CC=C1COC=2N=C(NCCNC(C)=O)N=CN2)C3=CC=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Russomanno P, et al. Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. J Med Chem. 2021;64(21):16020-16045. ?
molnova catalog
related products
  • BMS-8

    BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.

  • Avelumab

    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

  • LSD1-IN-24

    LSD1-IN-24 is a selective and potent LSD1 inhibitor with an IC50 value of 0.247 μM.LSD1-IN-24 induces PD-L1 expression and enhances the T cell killing response, and can be used in cancer-related diseases.